John Hennessee, MD
Psychiatry · Oklahoma City, OKNPI 1033147210
Payments from drug & device makers
What this record shows
Neuronetics, Inc. accounts for 72.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $2,534 and has fallen 94.0% since, to $153 in 2025.
Across 57 payments — averaging $60.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$186
- Johnson & Johnson$142
- Acadia Pharmaceuticals Inc$122
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$89
- AbbVie$82
- plus $315 from 9 others
What the payments were for
- Travel & lodging$1,56646%
- Food & beverage$1,85854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,424 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 118 | $395,095 |
| AustedoDeutetrabenazine | 17 | $90,245 |
| VraylarCariprazine Hcl | 36 | $61,607 |
| RexultiBrexpiprazole | 34 | $45,083 |
| TrintellixVortioxetine Hydrobromide | 51 | $30,092 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,065 |
| BelsomraSuvorexant | 39 | $18,103 |
| Clozapine | 176 | $16,672 |
| LatudaLurasidone Hcl | 13 | $16,671 |
| Clozapine OdtClozapine | 41 | $14,772 |
| Quetiapine Fumarate | 815 | $13,860 |
| Olanzapine | 370 | $12,181 |
| Lurasidone Hcl | 77 | $11,173 |
| Aripiprazole | 285 | $9,389 |
| Duloxetine Hcl | 377 | $8,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $142 | $395,095118 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $55 | $90,24517 claims |
| AbbVieVraylar | $82 | $61,60736 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $186 | $45,08334 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $63 | $30,09251 claims |
| Alkermes, Inc.Lybalvi | $24 | $19,06512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.